Nasdaq · CIK 0001701541
BDTX Black Diamond Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 21 d ago. Close $1.83 on Oct 9, 2026, +14% from the 52-week low and -62% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company
Price and insider trades, last year
BDTXOct 9, 2026 · close 1.83
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Black Diamond Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 57Moderate | Biotech Growth N V owner sell | $12M 5,784,292 shares | -68% | - |
Transactions
The last 36 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | Prakash Raman director | AGrant or award Common Stock | +6,801 | $1.93 | $13k | 51,840 | 21 d ago |
| Sep 18, 2026 | Ali Behbahani director | AGrant or award Common Stock | +7,707 | $1.93 | $15k | 110,236 | 21 d ago |
| Dec 12, 2025 | Prakash Raman director | AGrant or award Common Stock | +4,665 | $2.76 | $13k | 31,027 | Dec 15, 2025 |
| Dec 12, 2025 | Ali Behbahani director | AGrant or award Common Stock | +5,208 | $2.76 | $14k | 86,649 | Dec 15, 2025 |
| Sep 19, 2025 | Ali Behbahani director | AGrant or award Common Stock | +4,291 | $3.35 | $14k | 81,441 | Sep 22, 2025 |
| Sep 19, 2025 | Prakash Raman director | AGrant or award Common Stock | +3,843 | $3.35 | $13k | 26,362 | Sep 22, 2025 |
| Jun 20, 2025 | Ali Behbahani director | AGrant or award Common Stock | +6,170 | $2.33 | $14k | 77,150 | Jun 20, 2025 |
| Jun 20, 2025 | Prakash Raman director | AGrant or award Common Stock | +5,526 | $2.33 | $13k | 22,519 | Jun 20, 2025 |
| Jun 12, 2025 | Kapil Dhingra director | AGrant or award Stock Option (Right to Buy)derivative | +30,550 | $0.00 | $0 | 30,550 | Jun 12, 2025 |
| Jun 12, 2025 | Garry E Menzel director | AGrant or award Stock Option (Right to Buy)derivative | +30,550 | $0.00 | $0 | 30,550 | Jun 12, 2025 |
| Jun 12, 2025 | Prakash Raman director | AGrant or award Stock Option (Right to Buy)derivative | +30,550 | $0.00 | $0 | 30,550 | Jun 12, 2025 |
| Jun 12, 2025 | Shannon Campbell director | AGrant or award Stock Option (Right to Buy)derivative | +30,550 | $0.00 | $0 | 30,550 | Jun 12, 2025 |
| Jun 12, 2025 | Samarth Kulkarni director | AGrant or award Stock Option (Right to Buy)derivative | +30,550 | $0.00 | $0 | 30,550 | Jun 12, 2025 |
| Jun 12, 2025 | Ali Behbahani director | AGrant or award Stock Option (Right to Buy)derivative | +30,550 | $0.00 | $0 | 30,550 | Jun 12, 2025 |
| Mar 21, 2025 | Ali Behbahani director | AGrant or award Common Stock | +7,646 | $1.88 | $14k | 70,980 | Mar 21, 2025 |
| Mar 21, 2025 | Prakash Raman director | AGrant or award Common Stock | +6,848 | $1.88 | $13k | 16,993 | Mar 21, 2025 |
| Mar 19, 2025 | Biotech Growth N V owner | SOpen-market sale Common Stock | -1,000,000 | $2.07 | $2.1M | 7,517,839 | Mar 20, 2025 |
| Mar 19, 2025 | Biotech Growth N V owner | SOpen-market sale Common Stock | -300,000 | $1.94 | $583k | 7,217,839 | Mar 20, 2025 |
| Mar 19, 2025 | Biotech Growth N V owner | SOpen-market sale Common Stock | -1,000,000 | $2.31 | $2.3M | 6,217,839 | Mar 20, 2025 |
| Mar 19, 2025 | Biotech Growth N V owner | SOpen-market sale Common Stock | -2,000,000 | $2.00 | $4.0M | 4,217,839 | Mar 20, 2025 |
| Mar 19, 2025 | Biotech Growth N V owner | SOpen-market sale Common Stock | -400,000 | $2.09 | $837k | 3,817,839 | Mar 20, 2025 |
| Mar 19, 2025 | Biotech Growth N V owner | SOpen-market sale Common Stock | -584,292 | $1.95 | $1.1M | 3,233,547 | Mar 20, 2025 |
| Mar 19, 2025 | Biotech Growth N V owner | SOpen-market sale Common Stock | -500,000 | $2.12 | $1.1M | 2,733,547 | Mar 20, 2025 |
| Jan 30, 2025 | Elizabeth Buck CHIEF SCIENTIFIC OFFICER | AGrant or award Common Stock | +75,000 | $0.00 | $0 | 170,192 | Jan 31, 2025 |
| Jan 30, 2025 | Mark A. Velleca PRESIDENT & CEO | AGrant or award Common Stock | +75,000 | $0.00 | $0 | 121,522 | Jan 31, 2025 |
| Jan 30, 2025 | Sergey Yurasov CHIEF MEDICAL OFFICER | AGrant or award Common Stock | +75,000 | $0.00 | $0 | 75,000 | Jan 31, 2025 |
| Jan 30, 2025 | Erika Jones SEE REMARKS | AGrant or award Common Stock | +75,000 | $0.00 | $0 | 85,150 | Jan 31, 2025 |
| Jan 30, 2025 | Brent Hatzis-Schoch SEE REMARKS | AGrant or award Common Stock | +75,000 | $0.00 | $0 | 83,400 | Jan 31, 2025 |
| Jan 30, 2025 | Erika Jones SEE REMARKS | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Jan 31, 2025 |
| Jan 30, 2025 | Elizabeth Buck CHIEF SCIENTIFIC OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +175,000 | $0.00 | $0 | 175,000 | Jan 31, 2025 |
| Jan 30, 2025 | Brent Hatzis-Schoch SEE REMARKS | AGrant or award Stock Option (Right to Buy)derivative | +175,000 | $0.00 | $0 | 175,000 | Jan 31, 2025 |
| Jan 30, 2025 | Sergey Yurasov CHIEF MEDICAL OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Jan 31, 2025 |
| Jan 30, 2025 | Mark A. Velleca PRESIDENT & CEO | AGrant or award Stock Option (Right to Buy)derivative | +500,000 | $0.00 | $0 | 500,000 | Jan 31, 2025 |
| Dec 13, 2024 | Ali Behbahani director | AGrant or award Common Stock | +5,750 | $2.50 | $14k | 63,334 | Dec 16, 2024 |
| Dec 13, 2024 | Shannon Campbell director | AGrant or award Common Stock | +4,500 | $2.50 | $11k | 8,865 | Dec 16, 2024 |
| Dec 13, 2024 | Prakash Raman director | AGrant or award Common Stock | +5,150 | $2.50 | $13k | 10,145 | Dec 16, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Biotech Growth N Vowner
- Ali Behbahaniowner, director
- Elizabeth BuckCHIEF SCIENTIFIC OFFICER
- Shannon Campbelldirector
- Kapil Dhingradirector
- Brent Hatzis-SchochSEE REMARKS
- Erika JonesSEE REMARKS
- Samarth Kulkarniceo, officer, director
- Garry E Menzeldirector
- Prakash Ramandirector
- Mark A. VellecaPRESIDENT & CEO
- Sergey YurasovCHIEF MEDICAL OFFICER
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.